# **Navigating Iodine Intake in the Context of Thyroid Disease: A Comprehensive Analysis**

## **I. Introduction to Thyroid Disease and the Role of Iodine**

The thyroid gland, a small, butterfly-shaped endocrine organ situated in the lower front of the neck, plays a pivotal role in regulating numerous metabolic processes throughout the body.1 It achieves this by producing thyroid hormones, primarily thyroxine (T4​) and triiodothyronine (T3​), which are secreted into the bloodstream and carried to every tissue, influencing energy utilization, thermoregulation, and the proper functioning of the brain, heart, muscles, and other organs.2 Thyroid disease is an umbrella term for conditions that disrupt the normal functioning of this gland, leading to either an overproduction (hyperthyroidism) or underproduction (hypothyroidism) of thyroid hormones.1 Common causes include autoimmune disorders such as Graves' disease, which typically results in hyperthyroidism, and Hashimoto's disease (also known as Hashimoto's thyroiditis or chronic lymphocytic thyroiditis), which is the most common cause of hypothyroidism in iodine-sufficient regions.1 Other conditions include thyroid nodules, thyroiditis (inflammation of the thyroid), and thyroid cancer.1

Iodine is an essential trace mineral that is indispensable for thyroid hormone synthesis; indeed, the numbers in T4​ and T3​ refer to the number of iodine atoms in each hormone molecule.4 The thyroid gland must actively trap iodine from the bloodstream to produce these vital hormones.2 Given this fundamental role, the level of iodine intake can significantly impact thyroid health. However, the question of whether, and how, thyroid disease patients should control their iodine intake is complex and often fraught with conflicting advice.8 This report aims to synthesize current scientific understanding regarding iodine management for individuals with various thyroid conditions, drawing upon clinical guidelines, research findings, and expert opinions to provide a comprehensive overview.

## **II. The Dual Role of Iodine in Thyroid Health: Essential Nutrient and Potential Disruptor**

Iodine's relationship with the thyroid gland is a delicate balance; it is both an essential building block for thyroid hormones and, in certain circumstances, a potential disruptor of normal thyroid function. Understanding this dual role is crucial for comprehending dietary recommendations for thyroid patients.

### **A. Iodine as an Essential Micronutrient for Thyroid Hormone Synthesis**

Iodine is a critical trace element that the human body cannot produce on its own, making dietary intake essential.6 Its primary and most well-understood function is as a key component of the thyroid hormones thyroxine (T4​) and triiodothyronine (T3​).4 These hormones are vital for regulating metabolism, protein synthesis, enzymatic activity, and proper skeletal and central nervous system development, particularly in fetuses and infants.6 The thyroid gland actively concentrates iodide (the form in which iodine is absorbed) from the circulation to synthesize T4​ and T3​.7

The Recommended Dietary Allowance (RDA) for iodine for adult men and women (19+ years) is 150 micrograms (mcg) per day.6 Requirements increase during pregnancy (220-250 mcg/day) and lactation (250-290 mcg/day) to support fetal and infant development.6 The Tolerable Upper Intake Level (UL) for iodine for adults is 1,100 mcg per day; intake above this level is not recommended and may cause thyroid dysfunction.6 The American Thyroid Association (ATA) advises against daily iodine supplementation exceeding 500 mcg for adults and children, and during pregnancy and lactation, unless medically indicated and monitored.8

### **B. Consequences of Iodine Deficiency**

Insufficient iodine intake impairs the production of thyroid hormones, leading to a spectrum of disorders known collectively as iodine deficiency disorders (IDDs).9 The most common consequences are hypothyroidism (underactive thyroid) and goiter (enlargement of the thyroid gland).1 In an attempt to compensate for low iodine levels and maintain hormone production, the pituitary gland increases its secretion of thyroid-stimulating hormone (TSH).7 Elevated TSH stimulates the thyroid to trap more iodine and can lead to thyroid enlargement (goiter).7 Iodine deficiency is the leading cause of hypothyroidism and goiter worldwide, particularly in regions where iodized salt is not widely available or marine foods are not commonly consumed.1 Severe iodine deficiency, especially during pregnancy and early childhood, can lead to devastating outcomes such as cretinism (severe, irreversible intellectual disability and growth retardation), stillbirth, spontaneous abortion, and congenital abnormalities.9 Even mild to moderate deficiency during pregnancy can adversely affect fetal brain development.9 Globally, despite significant progress through salt iodization programs, iodine deficiency remains a public health concern, with an estimated 2.4% of the global population affected as of 2019.16

### **C. Risks Associated with Iodine Excess**

While essential, excessive iodine intake can also be detrimental to thyroid health, particularly in susceptible individuals.4 Iodine excess has been associated with hypothyroidism, hyperthyroidism, goiter development, and an increased risk or worsening of autoimmune thyroid diseases like Hashimoto's thyroiditis and potentially Graves' disease under certain circumstances.4 Individuals with pre-existing thyroid disease, the elderly, fetuses, and neonates are particularly vulnerable to the adverse effects of excess iodine.10

Two key physiological mechanisms describe the thyroid's response to acute iodine excess:

1. **The Wolff-Chaikoff Effect:** This is an autoregulatory phenomenon where a large intrathyroidal concentration of iodide transiently inhibits thyroid hormone synthesis and release, lasting approximately 24-48 hours.11 This effect protects the body from producing excessive thyroid hormones when exposed to a sudden iodine load. Normally, the thyroid gland "escapes" this inhibition by downregulating the sodium-iodide symporter (NIS), reducing further iodine uptake and allowing hormone synthesis to resume.11 However, if this escape mechanism fails, prolonged inhibition can lead to iodine-induced hypothyroidism.11 This failure to escape is more common in individuals with underlying autoimmune thyroiditis (like Hashimoto's) or other thyroid abnormalities.24
2. **The Jod-Basedow Phenomenon:** Conversely, in individuals with underlying thyroid autonomy (e.g., those with multinodular goiter, latent Graves' disease, or residing in iodine-deficient areas where autonomous nodules may have developed), an iodine load can lead to iodine-induced hyperthyroidism.9 In these cases, the autonomous thyroid tissue is not subject to normal TSH regulation and utilizes the excess iodine to overproduce thyroid hormones.

The widespread implementation of Universal Salt Iodization (USI) programs has dramatically reduced IDDs but has also led to discussions about potential increases in iodine excess and associated thyroid autoimmunity in some populations, particularly if these programs are not adequately monitored to prevent overly high iodine levels.17

## **III. Iodine Intake and Hypothyroidism (Including Hashimoto's Disease)**

The management of iodine intake in patients with hypothyroidism, particularly when it is due to Hashimoto's thyroiditis, is a subject of considerable discussion and varying recommendations.

### **A. General Hypothyroidism (Non-Deficiency Related)**

In regions with iodine sufficiency, such as the United States, iodine deficiency is not the most common cause of hypothyroidism.1 Autoimmune disease (Hashimoto's thyroiditis), surgical removal of the thyroid, or radiation treatment are more frequent causes.1 For hypothyroidism not caused by iodine deficiency, iodine supplements are generally not helpful and may even be harmful.30 The American Thyroid Association and other expert bodies advise against routine iodine supplementation in these patients, as excess iodine can potentially worsen hypothyroidism or induce other thyroid dysfunctions.4 The standard treatment for hypothyroidism is thyroid hormone replacement therapy, typically with levothyroxine, a synthetic form of T4​.2

The rationale is straightforward: if the thyroid gland's inability to produce hormones is due to autoimmune destruction or absence after surgery, providing extra iodine (the raw material) will not fix the underlying problem of a damaged or missing "factory." In such cases, the focus is on replacing the missing hormones directly. Introducing excess iodine might even further suppress any residual thyroid function due to the Wolff-Chaikoff effect, particularly in glands already compromised by autoimmunity.11

### **B. Hashimoto's Thyroiditis: The Autoimmune Dimension**

Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient areas and is characterized by the immune system attacking the thyroid gland.1 The role of iodine in Hashimoto's is particularly complex. While iodine is essential for thyroid hormone synthesis, excess iodine is considered an environmental factor that can trigger or exacerbate Hashimoto's in genetically predisposed individuals.8

Several mechanisms are proposed for how excess iodine might worsen Hashimoto's:

1. **Increased Immunogenicity of Thyroglobulin:** Higher levels of iodine incorporated into thyroglobulin (the protein precursor to thyroid hormones) can make it more immunogenic, meaning it is more likely to be recognized as "foreign" by the immune system, thereby intensifying the autoimmune attack.21
2. **Stimulation of Thyroid Peroxidase (TPO) Antibodies:** Some experts, like Dr. Datis Kharrazian, suggest that iodine stimulates TPO antibody production, which are hallmark antibodies in Hashimoto's, leading to increased autoimmune attack and worsened symptoms.8
3. **Oxidative Stress and Thyroid Cell Damage:** Excessive iodine can induce oxidative stress and apoptosis (cell death) in thyroid follicular cells, potentially releasing more autoantigens and fueling the autoimmune process.35 Research indicates that excessive iodine can promote pyroptosis (an inflammatory form of cell death) in thyroid follicular cells in Hashimoto's through pathways involving reactive oxygen species (ROS) and NLRP3 inflammasome activation.35

This understanding has led some functional and naturopathic practitioners to recommend a low-iodine diet for Hashimoto's patients, advising avoidance of iodine-rich foods like fish, seafood, seaweed, and iodized salt, as well as iodine supplements.8 The aim is to reduce the substrate that might be fueling the autoimmune attack. The American Thyroid Association (ATA) warns against supplementing with more than 500 mcg of iodine daily from sources like kelp or iodine supplements, as iodine excess is associated with hypothyroidism, elevated TSH, goiter, and Hashimoto's disease.8

However, there is no universal consensus on strict iodine restriction for all Hashimoto's patients, especially in iodine-sufficient populations where deficiency could also pose risks. The key concern is generally *excess* iodine. Most conventional endocrinologists emphasize avoiding iodine *supplements* and *excessive* dietary intake, rather than mandating a strictly low-iodine diet for all Hashimoto's patients, unless there is a specific clinical indication or if the patient is in a region of known iodine excess. The "optimal iodine window" for Hashimoto's patients—enough for hormone synthesis but not enough to exacerbate autoimmunity—remains an area of active discussion and research.42

The implementation of Universal Salt Iodization (USI) programs, while crucial for public health in preventing iodine deficiency, has been linked in some epidemiological studies to an increase in the prevalence of autoimmune thyroiditis, including Hashimoto's, particularly if these programs lead to excessive iodine intake without adequate monitoring.17 This observation underscores the delicate balance required in population-level iodine supplementation. While USI has dramatically reduced goiter and cretinism, the shift from iodine deficiency to sufficiency or excess may unmask or trigger autoimmune thyroid conditions in susceptible individuals. This does not negate the overall public health benefit of USI but highlights the need for continuous monitoring of both population iodine status and the incidence of thyroid disorders to ensure iodine intake remains within an optimal, safe range.

### **C. Impact of Varying Dietary Iodine Levels on Levothyroxine Therapy**

For patients with hypothyroidism (including that caused by Hashimoto's) who are treated with levothyroxine, the primary goal is to achieve and maintain a euthyroid state (normal thyroid hormone levels). The question arises whether dietary iodine intake significantly influences the absorption or efficacy of levothyroxine.

Levothyroxine absorption primarily occurs in the jejunum and upper ileum and can be affected by various factors, including food, certain medications (e.g., calcium, iron, antacids, proton pump inhibitors), and malabsorption syndromes.21 Dietary fiber can also reduce levothyroxine bioavailability.31 Patients are typically advised to take levothyroxine on an empty stomach, 30-60 minutes before breakfast or 3-4 hours after the last meal, to ensure consistent absorption.21

While extreme iodine deficiency could theoretically impair the thyroid's ability to utilize any residual function, most hypothyroid patients on adequate levothyroxine replacement have their thyroid hormone needs met exogenously. There is limited direct evidence from recent large-scale studies specifically quantifying how varying *dietary iodine* levels (within the normal to moderately excessive range, not pharmacological doses) directly impact *levothyroxine dosage requirements* or long-term TSH stability in well-managed, iodine-sufficient hypothyroid patients. Some sources suggest that individuals taking levothyroxine for hypothyroidism or goiter do not need to take iodine supplements, as their hormone replacement bypasses the need for the thyroid to synthesize hormones from iodine.46 The primary concern with iodine in these patients often shifts from ensuring enough iodine for hormone production to avoiding excess that could interfere with thyroid stability or exacerbate underlying autoimmunity in Hashimoto's.

The stability of levothyroxine dosage typically depends more on consistent absorption, body weight, pregnancy status, and interacting medications than on moderate fluctuations in dietary iodine in iodine-sufficient areas.21 However, significant changes in habitual iodine intake (e.g., starting high-dose kelp supplements) could potentially affect thyroid status, even in treated patients, and should be discussed with a healthcare provider. The lack of definitive, large-scale studies on this specific interaction represents an area where more research could be beneficial.

### **D. Long-Term Outcomes and Quality of Life in Hashimoto's Disease: The Iodine Question**

Hashimoto's disease is a chronic condition, and even with levothyroxine treatment to normalize TSH levels, some patients continue to experience symptoms that affect their quality of life (QoL).33 These symptoms can include fatigue, weight fluctuations, mood disturbances, and cognitive issues ("brain fog").33 The ongoing autoimmune process itself, independent of TSH levels, may contribute to these persistent symptoms.

The role of long-term dietary iodine intake in the progression of Hashimoto's, stability of antibody titers, and overall QoL in treated patients is not fully elucidated by large-scale, longitudinal studies with quantified iodine intake.19 One prospective case-control study found that euthyroid Hashimoto's patients on long-term levothyroxine treatment still had lower physical QoL scores compared to healthy controls, suggesting that effective control of hypothyroidism alone may not be sufficient to reduce all negative effects of the disease.47 This study did not specifically quantify or manipulate dietary iodine but highlights the unmet needs in managing QoL.

Some studies suggest that chronic exposure to excess iodine is associated with a higher prevalence of Hashimoto's and can exacerbate the autoimmune process.19 For instance, a study on patients with Hashimoto's who took a 250 mcg daily iodine supplement (in an area of mild iodine deficiency) showed that some developed thyroid dysfunction (hypothyroidism or hyperthyroidism), particularly those with pre-existing reduced echogenicity on ultrasound.49 This suggests that even moderate supplemental iodine can impact thyroid function in susceptible individuals with Hashimoto's. Another study indicated that excessive iodine promotes pyroptosis (inflammatory cell death) of thyroid follicular cells in Hashimoto's via oxidative stress pathways, potentially contributing to disease development.35

The "Thyroid Reset Diet" by Dr. Alan Christianson, which advocates for reducing excess dietary iodine, is based on the premise that such reduction can reverse hypothyroidism and Hashimoto's symptoms, citing research suggesting that proper dietary iodine intake can start to show benefits in as little as four weeks.40 Patient testimonials for such approaches often report symptomatic improvement, though rigorous, large-scale, long-term clinical trials are needed to fully validate these claims across diverse populations and compare them with standard management.

The lack of definitive, quantified long-term data on optimal iodine intake for treated Hashimoto's patients contributes to the ongoing "iodine controversy" and patient confusion.8 Future research focusing on longitudinal studies with careful quantification of iodine intake, alongside monitoring of antibody levels, thyroid function, medication requirements, and patient-reported outcomes, is crucial to provide clearer guidance.

## **IV. Iodine Intake and Hyperthyroidism (Including Graves' Disease and Toxic Nodular Goiter)**

In contrast to hypothyroidism, where iodine's role can be debated depending on the cause, the advice for most forms of hyperthyroidism is generally to avoid iodine excess.

### **A. General Hyperthyroidism and Iodine**

Hyperthyroidism, or overactive thyroid, occurs when the thyroid gland produces too much thyroid hormone.1 Excess iodine intake can be a cause of hyperthyroidism or can worsen pre-existing hyperthyroid conditions.1 This is particularly true in cases of the Jod-Basedow phenomenon, where individuals with underlying thyroid autonomy (like in nodular goiter) develop hyperthyroidism after exposure to an iodine load.9 Therefore, patients with hyperthyroidism are generally advised to avoid excess iodine from food, supplements (especially kelp), and certain medications.46 Healthcare providers should be consulted about which specific sources to avoid.51

### **B. Graves' Disease: Iodine's Role in Autoimmune Hyperthyroidism**

Graves' disease is an autoimmune disorder and the most common cause of hyperthyroidism.1 In Graves' disease, the immune system produces antibodies (thyroid-stimulating immunoglobulins, TSI, or TSH receptor antibodies, TRAb) that stimulate the thyroid gland to overproduce hormones.3

Historically, high doses of inorganic iodine (e.g., Lugol's solution or SSKI) have been used for short periods to treat severe hyperthyroidism (thyroid storm) and as a preoperative preparation for thyroidectomy in Graves' disease patients.10 This is due to the Wolff-Chaikoff effect, where large amounts of iodine temporarily inhibit thyroid hormone synthesis and release.11 However, this effect is usually transient.27

Regarding ongoing dietary iodine intake for Graves' patients, particularly those on antithyroid drugs (ATDs) like methimazole or propylthiouracil (PTU), the advice is evolving. While avoiding *excessive* iodine is standard due to its potential to fuel more hormone production 46, some recent research suggests that *insufficient* iodine intake might also be detrimental. A systematic review from 2023, analyzing studies on adult Graves' disease patients undergoing ATD therapy, tentatively concluded that *adequate* iodine intake (defined by WHO criteria as urinary iodine concentration [UIC] 100-199 µg/L) is associated with a lower recurrence rate of hyperthyroidism and better efficacy of ATDs in controlling thyrotoxicosis, compared to both insufficient (<100 µg/L) and above-requirements (200-299 µg/L) or excessive (≥300 µg/L) iodine intake.50 One randomized controlled trial included in this review found that optimal dietary iodine supplementation during ATD therapy was associated with lower recurrence rates than iodine restriction.57

These findings suggest a "U-shaped" curve where both too little and too much iodine can be problematic for Graves' disease management during ATD therapy. This contradicts older views that often recommended strict iodine restriction for all hyperthyroid patients.50 However, the evidence is still considered suboptimal by the review authors, who call for more high-quality, large-sample RCTs.50 Current international guidelines for Graves' disease management often do not provide detailed, specific recommendations on dietary iodine levels during ATD treatment, leading to confusion among patients and clinicians.50 The general advice remains to avoid iodine excess, particularly from supplements and high-iodine foods like kelp.46

### **C. Toxic Nodular Goiter (TNG) and Toxic Multinodular Goiter (TMNG)**

Toxic nodular goiter (a single overactive nodule, also called toxic adenoma) and toxic multinodular goiter (multiple overactive nodules) are conditions where one or more thyroid nodules autonomously produce excess thyroid hormones, independent of TSH stimulation, leading to hyperthyroidism.1 These conditions are more common in older individuals and in regions with historical or current iodine deficiency, as chronic iodine deficiency can promote the development of autonomous nodules.1

Patients with TNG or TMNG are particularly susceptible to iodine-induced hyperthyroidism (Jod-Basedow phenomenon).9 Exposure to excess iodine, whether from diet, supplements, or iodinated contrast media, can provide the substrate for these autonomous nodules to further increase hormone production, precipitating or worsening hyperthyroidism.1 Therefore, for patients with TNG/TMNG, avoidance of excess iodine is a critical aspect of management. Treatment for TNG/TMNG often involves definitive therapies like radioactive iodine ablation or surgery, as ATDs control symptoms but do not cure the underlying autonomy.58

### **D. Long-Term Outcomes and Quality of Life in Graves' Disease: The Iodine Connection**

Graves' disease is a chronic condition with a variable long-term course.66 Remission rates after a course of ATDs are approximately 50%, with many patients experiencing relapse, often within the first year.67 Factors influencing remission and relapse are complex and include TRAb levels, goiter size, and duration of ATD therapy.68

The role of ongoing dietary iodine intake in long-term remission maintenance and the prevention of complications like Thyroid Eye Disease (TED) is an area requiring more definitive research. As discussed, recent systematic reviews suggest that maintaining *adequate* (not deficient or excessive) iodine intake during ATD therapy might be associated with lower recurrence rates.50 One study noted that recurrence of Graves' disease is more common in iodine-deficient areas than in iodine-sufficient areas, and that iodine restriction in an iodine-excessive area did not improve ATD effectiveness or remission rates.68 However, another study from an iodine-replete area (Korea) found that excessive iodine intake did not increase the recurrence rate after ATD withdrawal, though the study did not compare this to an adequate or restricted intake group directly but rather looked at median UICs which were generally high.71

A long-term follow-up study (over 20 years) of Graves' disease patients in Norway found that only 34% were in remission at follow-up, with many requiring definitive treatment (RAI or surgery) or still using ATDs.67 Hypothyroidism was prevalent in those who achieved remission (21%), and this was associated with reduced QoL.67 This study did not specifically quantify dietary iodine intake over the long term but highlights the chronic and often relapsing nature of the disease and its impact on QoL. The study also noted that 47% of patients developed another autoimmune disease over the follow-up period.67

The evidence regarding dietary iodine's long-term impact on Graves' disease outcomes remains somewhat fragmented, with methodological limitations in many studies, including inconsistent definitions of iodine status and lack of long-term quantified dietary intake data.50 While avoiding gross excess is a clear recommendation, the precise optimal long-term dietary iodine strategy for maintaining remission and improving QoL in Graves' patients needs further investigation through robust, longitudinal studies.

## **V. Iodine Intake and Thyroid Nodules/Goiter**

Thyroid nodules (discrete lesions within the thyroid gland) and goiter (enlargement of the thyroid gland) are common thyroid conditions.59 Iodine status plays a significant role in their development and management.

### **A. Role of Iodine Deficiency in Nodule and Goiter Formation**

Iodine deficiency is a well-established and primary cause of both diffuse goiter and the formation of thyroid nodules worldwide.1 When iodine intake is insufficient, the thyroid gland cannot produce adequate amounts of thyroid hormone. This leads to increased TSH secretion from the pituitary gland, which stimulates thyroid cell growth and proliferation in an attempt to increase hormone production, resulting in thyroid enlargement (goiter).7 Over time, this chronic stimulation and heterogeneous growth can lead to the development of nodules within the goiter (multinodular goiter).14 In iodine-deficient areas, the prevalence of goiter and nodules is significantly higher.62 A recent systematic review and meta-analysis (2025) confirmed that iodine deficiency moderately increases the risk of developing thyroid nodules.72

### **B. Impact of Iodine Excess on Nodules and Goiter**

While iodine deficiency is a primary driver, iodine excess can also contribute to goiter formation, a phenomenon known as iodine-induced goiter.4 This is often due to the Wolff-Chaikoff effect, where high iodine levels inhibit thyroid hormone synthesis, leading to increased TSH and subsequent thyroid enlargement if the escape mechanism fails.11

The relationship between iodine *excess* and the *development* of thyroid nodules is less clear and more controversial than the link with deficiency.72 The 2025 systematic review and meta-analysis found inconsistent results for the association between more than adequate (>200 µg/L UIC) or excessive iodine intake (>300 µg/L UIC) and thyroid nodule risk, with no significant overall association found.72 Some studies have suggested a U-shaped relationship, where both deficiency and excess might increase nodule prevalence, but this was not confirmed by the meta-analysis.72 One cross-sectional study in Anhui Province, China, found varying prevalence of thyroid nodules in areas with deficient (21.9%), adequate (25.8%), and excess (18.0%) iodine intake, suggesting a complex, non-linear relationship.78 It is important to note that these studies often assess population iodine status rather than individual long-term intake, and cross-sectional designs limit causal conclusions.72

### **C. Pediatric Considerations for Iodine and Thyroid Nodules**

Children are also susceptible to thyroid nodules, and these carry a higher risk of malignancy compared to adults (19-26% vs 5-10%).79 Both chronic iodine deficiency and chronic iodine excess are listed as risk factors for thyroid nodules and differentiated thyroid carcinoma (DTC) in pediatric patients.79 This underscores the importance of maintaining an appropriate iodine balance throughout childhood and adolescence for thyroid health. Management goals in pediatric thyroid nodules focus on reducing comorbidity while maintaining remission and low disease-specific mortality.79

### **D. Long-Term Outcomes: Iodine Status, Nodule Growth, and Malignancy Risk**

The influence of ongoing iodine status on the growth of existing benign thyroid nodules or their risk of malignant transformation in iodine-sufficient populations is an area of ongoing research. One Korean study (an iodine-replete area) following patients with benign thyroid nodules found that 11.5% of nodules decreased in size and 13.5% increased over a median follow-up of 27 months.81 Factors like younger age and larger initial nodule size were associated with both increase and decrease in size, but dietary iodine levels of the participants were not specifically quantified or correlated with these changes beyond the general iodine-sufficient status of the region.81 The study did note that iodine deficiency is a known risk factor for changes in nodule size, and results from iodine-deficient areas might differ.81

Regarding malignancy risk, the relationship with iodine intake is complex. Iodine deficiency is thought to increase the risk of follicular thyroid cancer, potentially due to chronic TSH stimulation.77 Conversely, some ecological studies have suggested that a shift from iodine deficiency to sufficiency with iodization programs might be associated with an increase in papillary thyroid cancer (PTC) incidence, although this could also be influenced by increased detection rates.7 The highest incidence rates for thyroid cancer are reported in Japan, a country with traditionally high iodine intake.77 A 2015 review concluded that there is evidence that iodine deficiency increases the risk of follicular thyroid cancer and that iodine supplementation programs decrease its incidence, while the link between iodine intake and PTC is less clear and may be influenced by detection bias.77 A 2025 systematic review and meta-analysis on iodine intake and thyroid nodules did not find a consistent effect of more than adequate or excessive iodine intake on nodule development, and did not specifically address malignancy risk within nodules.72

The current evidence does not provide definitive, quantified dietary iodine recommendations for the specific purpose of preventing benign nodule growth or malignant transformation in iodine-sufficient individuals. The focus remains on maintaining overall iodine sufficiency while avoiding extremes. Further prospective studies are needed to clarify the causal relationship between various levels of iodine intake and the natural history of thyroid nodules, including growth and malignancy risk, especially in iodine-replete populations.72

## **VI. Sources of Iodine: Implications for Thyroid Patients**

Managing iodine intake requires an understanding of its various sources, which can be broadly categorized into diet, supplements, and medical exposures. The variability and sometimes hidden nature of these sources pose particular challenges for individuals with thyroid conditions who need to control their intake.

### **A. Dietary Sources and Their Inherent Variability**

Common dietary sources of iodine include seafood (fish like cod and tuna, shellfish), seaweed (kelp, nori, kombu, wakame), dairy products (milk, yogurt, cheese), eggs, and iodized salt.6 Some breads made with iodate dough conditioners can also be a significant source.7

A critical challenge for anyone trying to manage iodine intake is the profound variability in iodine content, even within the same food category.8

* **Seaweed:** This is perhaps the most variable source. Different types of seaweed can contain vastly different amounts of iodine, ranging from relatively moderate to extremely high levels, sometimes thousands of times the RDA in a single serving.6 For example, kelp is notoriously high in iodine.8 This makes casual consumption of seaweed products risky for those needing to avoid excess.
* **Dairy Products:** The iodine content in dairy can fluctuate based on agricultural practices, such as the use of iodine-containing feed for cattle and iodine-based sanitizing agents (iodophors) in milking equipment and processing.88
* **Processed Foods:** Many processed foods, like canned soups, almost never contain iodized salt, but labeling practices can make it difficult to determine the iodine content or type of salt used.84
* **Restaurant Foods:** It is often impossible to ascertain whether iodized salt is used in restaurant meals, making it a significant unknown for those on restricted iodine diets.92
* **Hidden Sources:** Iodine can also be present in unexpected places, such as FD&C red dye #3 (erythrosine), found in some maraschino cherries, beverages, and candies, and certain dough conditioners used in commercial bakery products.84

This inherent variability and the presence of hidden sources mean that simply avoiding a few "high-iodine" foods may not be sufficient for precise iodine control. It necessitates careful label reading (where information is available), awareness of food preparation methods, and caution with processed and restaurant foods, especially for individuals on medically supervised low-iodine diets (e.g., prior to radioactive iodine therapy for thyroid cancer) or for those with conditions like Hashimoto's who are advised by some practitioners to limit iodine.

The following table summarizes common dietary sources and their relative iodine content, highlighting the variability:

| **Food Category** | **Specific Examples** | **Typical Iodine Content per serving (mcg)** | **Notes on Variability & %DV (based on 150 mcg RDA)** | **Snippet References** |
| --- | --- | --- | --- | --- |
| **Seaweed** | Kelp, Nori, Kombu, Wakame | Highly variable: Nori (2 Tbsp, 5g): 116 mcg (77% DV). Kelp can be much higher. | Iodine content varies enormously by type, origin, and preparation. Kelp can contain thousands of mcg per serving. **Extreme caution advised for those needing to limit iodine.** | 6 |
| **Fish & Shellfish** | Cod (baked, 3 oz), Tuna, Shrimp | Cod: 146 mcg (97% DV). Tuna (canned, light, 3 oz): ~17-30 mcg. | Generally good sources. Content varies by species and whether saltwater or freshwater. | 6 |
| **Dairy Products** | Milk (1 cup), Yogurt (1 cup), Cheese | Milk: ~56-150+ mcg. Yogurt: ~75-150 mcg. Cheese: variable. | Iodine content depends on cattle feed, use of iodophor sanitizers. Significant source in many Western diets. | 6 |
| **Eggs** | 1 large egg | ~24-26 mcg | Primarily in the yolk. A good, consistent source. | 6 |
| **Iodized Salt** | ¼ teaspoon | ~71-78 mcg (47-52% DV) | A primary source in many countries due to fortification programs. | 6 |
| **Bread (made with iodate dough conditioner)** | White or Whole-wheat (2 slices) | ~273-296 mcg (182-197% DV) | Can be a very significant hidden source if iodate conditioners are used. Label reading is crucial. Not all breads use these. | 7 |
| **Fruits & Vegetables** | Most types | Generally low (e.g., <10 mcg per serving) | Iodine content depends on soil iodine levels, which vary geographically. Not primary sources unless grown in iodine-rich soil or contaminated. | 11 |
| **Meat & Poultry** | Beef liver, Chicken | Moderate, variable. Beef liver (3 oz): ~14 mcg. Chicken: variable. | Not typically high sources unless feed is supplemented or processed with iodine-containing substances. | 6 |

*Note: DV = Daily Value. Iodine content can vary significantly. This table is for illustrative purposes.*

### **B. Iodized Salt: A Public Health Strategy and Its Implications for Thyroid Patients**

The iodization of salt is the most widely adopted and successful public health measure to combat iodine deficiency disorders on a global scale.1 In countries with effective salt iodization programs, like the United States, iodine deficiency in the general population has become uncommon.1 Currently, about 88% of households worldwide use iodized salt.9

However, it is crucial to recognize that not all salt available to consumers is iodized. Specialty salts, such as sea salt, kosher salt, Himalayan salt, and fleur de sel, are generally *not* iodized.84 Furthermore, processed foods, which constitute a significant portion of many diets, often utilize non-iodized salt, and food labels may not always specify the type of salt used.84

For the general population, iodized salt serves as a reliable "default" source of iodine, ensuring adequate intake. However, for individuals with specific thyroid conditions who are advised to restrict their iodine intake—such as those preparing for radioactive iodine (RAI) therapy for thyroid cancer or some patients with Hashimoto's following particular dietary protocols—the widespread presence of iodized salt becomes a significant management challenge.8 These individuals must exercise heightened vigilance, scrutinizing food labels, inquiring about ingredients in restaurant meals, and often preparing most of their food at home using non-iodized salt to maintain control over their iodine consumption. This can impose considerable lifestyle adjustments and increase the burden of dietary management. The success of USI in preventing deficiency must be balanced with awareness of these implications for specific patient subgroups.

### **C. Iodine Supplements: When Are They Indicated, and When to Avoid?**

Iodine is available in dietary supplements, typically in the form of potassium iodide or sodium iodide, and also in kelp-based supplements.6 Despite their availability, iodine supplements are generally **not recommended** for individuals with thyroid disease unless a healthcare professional has confirmed an iodine deficiency and specifically advises supplementation.30

The American Thyroid Association (ATA) explicitly advises against the ingestion of iodine and kelp supplements containing in excess of 500 mcg of iodine daily for children and adults, including during pregnancy and lactation (unless under specific medical guidance for deficiency).8 This is because many over-the-counter iodine and kelp supplements contain iodine in amounts that are several thousand times higher than the daily Tolerable Upper Limit (UL) of 1,100 mcg for adults.10

* **For Hypothyroidism:** If hypothyroidism is not caused by iodine deficiency (which is common in iodine-sufficient regions), taking iodine supplements will not help and can, in fact, worsen the condition or induce other thyroid problems.4
* **For Hyperthyroidism:** Iodine supplements are unnecessary and can exacerbate hyperthyroidism by providing more substrate for hormone production, potentially counteracting the effects of antithyroid drug (ATD) treatment.46
* **For Hashimoto's Thyroiditis:** Excess iodine from supplements can stimulate thyroid peroxidase (TPO) antibody production and increase the autoimmune attack on the thyroid gland, worsening the condition.8

The primary exception where iodine supplementation is often recommended is during **pregnancy and lactation**. Women in these life stages have increased iodine requirements (RDA of 220 mcg and 290 mcg, respectively) to support fetal and infant brain development.6 The ATA recommends that women take a prenatal multivitamin containing 150 mcg of iodine daily (usually as potassium iodide) during preconception, pregnancy, and lactation, even in generally iodine-sufficient areas, to ensure these increased needs are met.10 However, even in this group, high-dose iodine supplements are not always advised and should be guided by a healthcare professional, as they can cause thyroid problems in some women.6

The ease of access to high-dose iodine and kelp supplements, often misleadingly marketed as "thyroid boosters" or for general thyroid health, poses a significant risk of inadvertent over-supplementation.8 Individuals, particularly those with diagnosed or undiagnosed thyroid conditions like Hashimoto's or nodular goiter, may self-prescribe these supplements seeking relief from symptoms, unaware of the potential harm. This can lead to iodine excess, triggering or worsening thyroid dysfunction. Therefore, patient education on the risks of unmonitored iodine supplementation is paramount.

### **D. Iodine in Medications and Medical Contrast Agents**

Beyond diet and supplements, certain medications and medical imaging agents can be significant sources of iodine, capable of impacting thyroid function.

* **Amiodarone:** This antiarrhythmic drug is well-known for its high iodine content (approximately 37% iodine by weight, with each 200 mg tablet containing about 75 mg of organic iodine, releasing about 6 mg of free iodine daily).24 Amiodarone can induce both hypothyroidism (due to a persistent Wolff-Chaikoff effect, especially in patients with underlying Hashimoto's) and hyperthyroidism (Type 1, due to increased hormone synthesis in an abnormal gland, or Type 2, a destructive thyroiditis).1
* **Other Medications:** Some expectorants (e.g., SSKI - saturated solution of potassium iodide), topical antiseptics (e.g., povidone-iodine), and certain vitamin/mineral preparations can also contain substantial amounts of iodine.3 Patients should be aware of these potential sources, especially if they have underlying thyroid conditions.
* **Iodinated Contrast Media (ICM):** These agents are widely used for diagnostic imaging procedures such as computed tomography (CT) scans and angiography.6 A single dose of ICM can deliver a supraphysiological iodine load, ranging from 18 to 45 grams of iodine (18,000,000 to 45,000,000 mcg), which is many thousands of times the daily RDA.96 While most individuals with normal thyroid function tolerate this acute iodine exposure, it can induce thyroid dysfunction (both hypothyroidism and hyperthyroidism) in susceptible individuals.23 The prevalence of ICM-induced thyroid dysfunction is estimated to be between 1% and 15%.23
  + **Risk factors for ICM-induced hyperthyroidism** include pre-existing non-toxic nodular goiter, latent Graves' disease, and residence in iodine-deficient areas.23
  + **Risk factors for ICM-induced hypothyroidism** include underlying autoimmune thyroiditis (Hashimoto's), living in iodine-replete areas (where the thyroid may be more sensitive to the inhibitory effects of iodine), a history of postpartum or subacute thyroiditis, prior hemithyroidectomy, and fetal/neonatal exposure.23

The European Thyroid Association (ETA) has published guidelines for the management of ICM-induced thyroid dysfunction, emphasizing an individualized approach to prevention and treatment based on risk factors.96 Monitoring of thyroid function before and after ICM administration may be warranted for at-risk patients.10

The substantial iodine load from these medical sources often goes unrecognized by patients and even by non-endocrinologist clinicians as a potential cause of subsequent thyroid issues. This "hidden" iodine burden can lead to diagnostic challenges if thyroid dysfunction develops and the link to prior iodine exposure is not considered. Greater awareness across medical disciplines and improved patient counseling regarding iodine-containing medical products are essential to mitigate these risks.

## **VII. Goitrogenic Foods: Understanding Their Impact on Thyroid Function**

Beyond iodine itself, certain foods contain compounds known as goitrogens, which can potentially interfere with thyroid function. However, the clinical relevance of these foods for most thyroid patients, particularly in iodine-sufficient populations, is often overstated.

### **A. What Are Goitrogens and How Do They Work?**

Goitrogens are naturally occurring substances found in various plant-based foods that can disrupt the normal synthesis of thyroid hormones.63 Their primary mechanisms of action include:

1. **Inhibiting Iodine Uptake:** Some goitrogens can interfere with the thyroid gland's ability to take up iodide from the bloodstream, a crucial first step in hormone production.100
2. **Interfering with Thyroid Peroxidase (TPO):** Other goitrogens can inhibit the activity of TPO, the enzyme responsible for oxidizing iodide and incorporating it into thyroglobulin to form thyroid hormones.100

Common foods containing goitrogenic compounds include 8:

* **Cruciferous Vegetables:** This large family includes broccoli, cauliflower, kale, cabbage, Brussels sprouts, collard greens, bok choy, radishes, and turnips. They contain glucosinolates, which can be broken down into goitrogenic compounds like thiocyanates.
* **Soy Products:** Soybeans and soy-based foods (tofu, soy milk, edamame) contain isoflavones, which can have goitrogenic activity, primarily by inhibiting TPO.
* **Millet:** This grain contains goitrogenic compounds.
* **Cassava (Yuca):** This root vegetable contains cyanogenic glucosides, which can be metabolized to thiocyanates.
* **Other Foods:** Peanuts, pine nuts, strawberries, peaches, and sweet potatoes also contain goitrogenic substances, though generally in smaller amounts.

If consumed in very large quantities, particularly in the context of coexisting iodine deficiency, goitrogens have the potential to decrease thyroid hormone production, leading to an increase in TSH and subsequent goiter formation or hypothyroidism.100

### **B. Relevance for Thyroid Patients, Especially in Iodine-Sufficient Individuals**

For the majority of individuals with normal thyroid function and adequate iodine intake, the consumption of goitrogenic foods in typical dietary amounts is not a cause for concern and is, in fact, generally encouraged due to their rich nutritional profile (vitamins, minerals, fiber, and antioxidants).84

Several factors mitigate the potential impact of goitrogens:

* **Cooking:** Heat deactivates a significant portion of the goitrogenic compounds in many vegetables. Steaming, boiling, or fermenting can reduce their goitrogenic potential.100
* **Iodine Status:** The goitrogenic effect of these foods is most pronounced when iodine intake is low.100 In iodine-sufficient individuals, the thyroid can typically compensate for the mild inhibitory effects of moderate goitrogen consumption.
* **Quantity:** Problems related to goitrogens generally only arise from the consumption of *extremely large quantities* of these foods, particularly in their raw state.90

For patients with diagnosed thyroid conditions:

* **Hypothyroidism (especially Hashimoto's):** Individuals with an underactive thyroid, particularly if they still have some residual thyroid function (as in early Hashimoto's), might be advised by some practitioners to be cautious about *excessive* intake of *raw* goitrogenic foods.90 However, complete avoidance is rarely necessary if iodine intake is adequate and the foods are mostly cooked. The focus for Hashimoto's is often more on managing autoimmunity and ensuring adequate hormone replacement than on strict avoidance of goitrogens.
* **Soy Products:** The primary concern with soy for hypothyroid patients on levothyroxine is its potential to interfere with the absorption of the medication if consumed at the same time.87 It is generally recommended to separate soy intake from levothyroxine administration by several hours. Soy itself is unlikely to significantly impair thyroid function in iodine-sufficient individuals already on adequate thyroid hormone replacement.
* **Thyroid Nodules:** There is a lack of specific, evidence-based guidelines from major thyroid associations (ATA, ETA, Endocrine Society) recommending strict avoidance of goitrogenic foods for euthyroid, iodine-sufficient patients with thyroid nodules.60 The development of nodules is more strongly linked to iodine deficiency than to moderate goitrogen intake in iodine-replete settings.63

The fear of goitrogenic foods among thyroid patients often appears to be disproportionate to the actual risk, especially in iodine-sufficient populations. This can lead to unnecessary dietary restrictions, potentially depriving individuals of nutrient-dense foods. The impact of goitrogens is highly contextual, depending on the individual's iodine status, the quantity and preparation method of the goitrogenic foods, and their overall thyroid health. In iodine-sufficient individuals, the goitrogenic effect is usually clinically insignificant with normal dietary patterns.

The following table provides practical advice for the consumption of common goitrogenic foods:

| **Food Category** | **Specific Examples** | **Goitrogenic Compound(s) (if known)** | **Practical Advice for Thyroid Patients** |
| --- | --- | --- | --- |
| **Cruciferous Vegetables** | Broccoli, Cauliflower, Kale, Cabbage, Brussels Sprouts | Glucosinolates (-> Thiocyanates) | Generally safe and nutritious in moderation, especially when cooked, if iodine intake is adequate. Excessive raw consumption might be a concern for those with active hypothyroidism and some residual thyroid function. 90 |
| **Soy Products** | Soybeans, Tofu, Soy Milk, Edamame | Isoflavones | Can interfere with levothyroxine absorption; separate intake from medication by at least 4 hours. Unlikely to harm thyroid function in iodine-sufficient individuals with normal or treated thyroid function when consumed in moderation. 90 |
| **Millet** |  | Goitrogenic compounds | Excessive consumption might be problematic, particularly if iodine intake is low. |
| **Cassava (Yuca)** |  | Cyanogenic glucosides (-> Thiocyanates) | Proper processing (e.g., soaking, cooking) is important to reduce goitrogens. Concern mainly with high, chronic intake in iodine-deficient areas. |
| **Other Foods** | Peanuts, Pine Nuts, Strawberries, Peaches, Sweet Potatoes | Various | Generally considered safe in normal dietary amounts. The goitrogenic effect is typically weak and unlikely to be clinically significant unless consumed in extremely large quantities with concurrent iodine deficiency. 102 |

## **VIII. Navigating the Iodine Maze: Controversies, Research Gaps, and Patient Guidance**

The relationship between iodine and thyroid disease is undeniably complex, leading to ongoing debates, significant patient confusion, and a clear need for more nuanced guidance and research.

### **A. The "Iodine Controversy": Differing Expert Opinions and Resulting Patient Confusion**

A notable "iodine controversy" exists, particularly concerning autoimmune thyroid disease, primarily Hashimoto's thyroiditis.8 On one side, some practitioners, often in the realm of functional or integrative medicine, advocate for very low iodine intake or strict avoidance of iodized salt and iodine-rich foods for individuals with Hashimoto's.8 Their rationale is that iodine, especially in excess of basic physiological needs, can act as an environmental trigger or exacerbate the autoimmune process by increasing the immunogenicity of thyroglobulin or stimulating TPO antibody production.8 Patient anecdotes and some smaller studies sometimes support symptomatic improvement with such restrictions.

On the other side, conventional endocrinology generally emphasizes ensuring iodine sufficiency to prevent deficiency-related thyroid problems, while cautioning against high-dose iodine supplementation unless a deficiency is confirmed.30 For Hashimoto's patients in iodine-sufficient regions, the mainstream advice typically does not involve aggressive dietary iodine restriction beyond avoiding clear excess (e.g., from kelp supplements or pharmacological doses). The focus is on thyroid hormone replacement to manage hypothyroidism.

This divergence in expert opinion creates a confusing landscape for patients. Individuals diagnosed with Hashimoto's or other thyroid conditions often encounter conflicting advice from different healthcare providers, online sources, and patient communities.8 This uncertainty can lead to anxiety about food choices, adherence to overly restrictive diets without clear benefit, or, conversely, inadvertent consumption of excessive iodine from supplements marketed for "thyroid support." A systematic review on iodine intake in Graves' disease explicitly noted that patients are often confused about whether to use iodized or non-iodized salt and that international guidelines frequently avoid detailed discussion on this issue due to lack of definitive evidence, leaving clinicians and patients in a difficult position.50 Qualitative studies have highlighted patient distress and confusion related to dietary restrictions, particularly the low-iodine diet (LID) for RAI therapy, but similar confusion likely extends to everyday iodine management for other thyroid conditions given the mixed messages.107

This "information vacuum" arises from the lack of definitive, universally accepted, high-level evidence-based guidelines that provide precise, quantified dietary iodine targets for the daily management of *specific* autoimmune thyroid conditions in iodine-sufficient environments. While RDAs and ULs exist for the general population, translating these into tailored advice for individuals with active thyroid autoimmunity or varying degrees of thyroid dysfunction is challenging. Research in this area is ongoing, but often hampered by methodological limitations, such as accurately quantifying long-term individual iodine intake and the heterogeneity of patient populations.15

### **B. Universal Salt Iodization (USI): Balancing Benefits with Potential Autoimmune Concerns**

Universal Salt Iodization (USI) has been a cornerstone of global public health, dramatically reducing the prevalence of iodine deficiency disorders (IDDs) like goiter and cretinism.7 However, the introduction of USI programs, particularly if not meticulously monitored to prevent excessive population-level iodine intake, has been temporally associated in some regions with an increased incidence or prevalence of autoimmune thyroid diseases (AITD), especially Hashimoto's thyroiditis.17

The proposed mechanism is that a rapid shift from iodine deficiency to sufficiency, or even excess, can unmask or trigger autoimmunity in genetically susceptible individuals.17 Excess iodine can increase the iodination of thyroglobulin, making it more antigenic, and can also induce oxidative stress within thyroid cells, potentially leading to inflammation and cell damage that exposes thyroid autoantigens to the immune system.16

It is important to note that this association is complex. Some research suggests that while there might be a short-term modulation of autoimmune markers or a transient increase in AITD after USI introduction, long-term, well-monitored USI programs may be safe and not lead to a sustained rise in clinically significant autoimmune thyroid disease.29 The critical factor appears to be the level of iodine intake achieved and maintained at the population level. Iodine sufficiency is beneficial, but iodine excess can be problematic for thyroid autoimmunity. This underscores the "double-edged sword" nature of USI: immensely beneficial in eradicating IDDs, but requiring careful and continuous surveillance of population iodine status to avoid pushing intake into ranges that might increase the risk of AITD in susceptible subgroups. The goal is to find the optimal population iodine intake that minimizes both deficiency and excess-related disorders.

### **C. Unanswered Questions and Future Research Directions in Iodine and Thyroid Health**

Despite extensive research, significant knowledge gaps and areas requiring further investigation persist in the field of iodine and thyroid health:

* **Optimal Iodine Window for Autoimmune Thyroid Disease:** The precise range of daily iodine intake that is optimal for patients with Hashimoto's thyroiditis – balancing the need for hormone synthesis against the risk of exacerbating autoimmunity – is not definitively established, especially in iodine-sufficient populations.19 Similarly, for Graves' disease patients on ATDs, while "adequate" intake seems better than deficient or excessive, more precise long-term targets are needed.50
* **Long-Term Effects of Chronic Moderate Iodine Excess:** The long-term clinical consequences (symptoms, antibody titers, thyroid gland size, levothyroxine dose stability, QoL) of chronic *moderate* iodine excess (e.g., intakes slightly above RDA but below pharmacological doses) in patients already diagnosed and treated for Hashimoto's thyroiditis are not well characterized by robust longitudinal studies.19
* **Iodine and Levothyroxine Interaction:** More specific research is needed on how varying levels of habitual dietary iodine intake affect levothyroxine absorption, bioavailability, and ultimate dosage requirements in hypothyroid patients.31
* **Iodine in Graves' Disease Remission and Complications:** The role of long-term dietary iodine management in maintaining remission after ATD withdrawal and in preventing or mitigating complications like Thyroid Eye Disease (TED) in Graves' patients requires further study.19
* **Iodine and Thyroid Nodules/Cancer:** The causal relationship between different levels of iodine intake (especially excess) and the development, growth, or malignant transformation of thyroid nodules needs more definitive prospective studies. Current evidence is often from cross-sectional or ecological studies, with inconsistencies.7
* **Goitrogens in Iodine-Sufficient Populations:** Clear guidelines on the consumption of goitrogenic foods for individuals with thyroid nodules or Hashimoto's who are iodine-sufficient are lacking.60
* **Individual Variability:** A significant challenge is understanding the substantial inter-individual variability in thyroid response to iodine. Genetic predispositions (e.g., for autoimmunity), baseline thyroid health, gut microbiome composition, and concurrent nutritional status (e.g., selenium, iron, vitamin D deficiencies) likely modulate how an individual's thyroid reacts to different iodine levels.10 Population-based RDAs and ULs may not be optimal for all individuals, especially those with thyroid vulnerabilities. Future research should aim to identify biomarkers or genetic profiles that could predict individual sensitivity to iodine, paving the way for more personalized intake recommendations.
* **Methodological Challenges:** Accurately assessing an individual's long-term habitual iodine intake is notoriously difficult.15 Dietary recall methods are prone to bias, food iodine content databases are often incomplete or show wide regional and preparation-dependent variations, and spot urinary iodine concentrations (the most common biomarker) only reflect very recent intake and exhibit high intra-individual variability.25 These methodological hurdles significantly complicate the design and interpretation of large-scale, long-term epidemiological studies needed to definitively answer many outstanding questions about chronic iodine exposure and thyroid health. Developing more reliable and feasible methods for assessing long-term iodine status is a research priority.

### **D. Patient Education and Empowerment: Addressing Confusion and Unmet Needs**

The existing confusion surrounding dietary iodine management highlights significant gaps in patient education and unmet needs for clear, consistent, and actionable guidance.32 Patients often turn to online resources, which may provide conflicting or inaccurate information, further compounding their uncertainty.106 Qualitative studies reveal that patients, particularly those undergoing treatments like RAI therapy which involve strict low-iodine diets, experience significant dietary disruption, distress, and feelings of isolation.107 While these studies focus on the temporary LID, the underlying themes of confusion about iodine-containing foods and the impact of dietary restrictions on daily life likely resonate with patients trying to navigate everyday iodine intake for chronic thyroid conditions.

There is a clear need for healthcare providers to:

* Proactively discuss iodine with their thyroid patients, explaining its role and the rationale behind any specific dietary advice.
* Provide clear, practical, and individualized guidance on iodine intake based on the patient's specific condition, local iodine environment, and treatment plan.
* Acknowledge the controversies and help patients navigate conflicting information from various sources.
* Direct patients to reliable resources for information on dietary iodine, such as those provided by major thyroid associations.

Patient advocacy groups play a crucial role in providing support and information, but even their resources may not always offer definitive answers to every nuanced question about daily iodine management outside of specific contexts like RAI preparation.21 Empowering patients with accurate knowledge and involving them in shared decision-making regarding dietary choices is essential for improving adherence, reducing anxiety, and enhancing overall well-being.

## **IX. Clinical Guidelines and Recommendations on Iodine Intake**

Major thyroid and endocrine societies provide guidelines on iodine intake, though specific dietary advice for ongoing management of all thyroid conditions can vary in detail and is an evolving area.

### **A. American Thyroid Association (ATA)**

The ATA provides several key recommendations and statements regarding iodine:

* **General Intake:** Recognizes the RDA for adults (150 mcg/day) and the UL (1,100 mcg/day).10
* **Iodine Deficiency:** Acknowledges that iodine deficiency is the most common cause of hypothyroidism worldwide but is rare in the U.S. due to salt iodization.1
* **Iodine Excess:** Warns that excess iodine can cause thyroid dysfunction (hypothyroidism or hyperthyroidism) and advises against routine daily iodine supplements exceeding 500 mcg, especially from kelp, unless medically indicated and monitored.8 Individuals with pre-existing thyroid disease are particularly susceptible to adverse effects of excess iodine.10
* **Hypothyroidism:** States that if hypothyroidism is not due to iodine deficiency, iodine supplements are not helpful and can worsen the condition.30
* **Hyperthyroidism (Graves'):** While specific dietary iodine levels for ongoing ATD treatment are not detailed extensively in general patient information, the ATA guidelines for hyperthyroidism management (2016) acknowledge that iodine-containing medications and contrast agents can induce or exacerbate hyperthyroidism.129 High-dose iodine (Lugol's solution or SSKI) is indicated for short-term use in severe hyperthyroidism (thyroid storm) and preoperatively for Graves' disease.10
* **Pregnancy and Lactation:** Strongly recommends that women take a multivitamin containing 150 mcg of iodine daily during preconception, pregnancy, and lactation to meet increased needs.10
* **Iodinated Contrast Media (ICM):** Acknowledges that patients receiving large amounts of iodine in ICM should be monitored for iodine-induced thyroid dysfunction if risk factors are present.10
* **Low-Iodine Diet (LID):** Provides detailed guidance on a LID (typically <50 mcg/day) for patients undergoing radioactive iodine (RAI) therapy for thyroid cancer to enhance RAI uptake.92 This is a *temporary, specific* dietary intervention, not a general recommendation for other thyroid conditions.
* **Thyroid Nodules:** Notes that iodine deficiency can cause nodules, but specific dietary iodine guidelines for managing existing nodules in iodine-sufficient individuals are not prominent beyond ensuring overall iodine adequacy and avoiding deficiency or excess.59 The 2015 ATA guidelines for thyroid nodules and differentiated thyroid cancer focus on diagnosis and risk stratification rather than specific dietary iodine management for nodules themselves.129

### **B. European Thyroid Association (ETA)**

The ETA also provides relevant guidelines:

* **Iodinated Contrast Media (ICM):** The 2021 ETA Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction are comprehensive.96 They highlight that ICM can induce hyperthyroidism (especially in iodine-deficient regions or patients with nodular goiter/latent Graves') and hypothyroidism (especially in patients with autoimmune thyroiditis in iodine-sufficient areas). They recommend an individualized approach to prevention and treatment based on risk factors and iodine intake.96
* **Graves' Hyperthyroidism:** The 2018 ETA Guideline for the Management of Graves' Hyperthyroidism primarily focuses on ATDs, RAI, and surgery.131 While it discusses factors affecting ATD efficacy, specific quantified dietary iodine intake recommendations for patients on ATDs are not a central feature, though the general principle of avoiding iodine excess would apply. The guidelines do recommend a prolonged course of ATD treatment (3 years or more).132
* **Thyroid Nodules:** The 2023 ETA Clinical Practice Guidelines for Thyroid Nodule Management focus on initial workup, risk stratification (using EU-TIRADS), FNA biopsy, and management based on cytopathology, including active surveillance and minimally invasive treatments.131 These guidelines do not appear to provide specific recommendations regarding dietary iodine intake or goitrogen consumption for patients with thyroid nodules, especially in iodine-sufficient euthyroid individuals. The primary concern related to iodine and nodules in a global context is deficiency leading to goiter and nodule formation.62
* **Iodine as an Endocrine Disruptor:** In a 2023 joint statement with the European Society of Endocrinology (ESE), the ETA clarified that while *excess* iodine (particularly from antiseptics or high-dose exposures) can disrupt thyroid function, elemental iodine/iodide itself, when appropriately supplied, is an essential micronutrient, not an endocrine disruptor in the typical sense.136 This statement aimed to correct potential misinterpretations of an ECHA classification.

### **C. Other International Guidelines (WHO, Asian Thyroid Associations)**

* **World Health Organization (WHO):** The WHO focuses on population-level iodine nutrition, recommending USI to prevent IDDs.7 They define population iodine status based on median urinary iodine concentrations (UIC), e.g., adequate intake for school-age children is a median UIC of 100-199 µg/L, and for pregnant women, 150-249 µg/L.9 These are public health targets, not individualized clinical guidelines for patients with existing thyroid disease, though they provide context for "iodine sufficiency."
* **Japanese Thyroid Association (JTA):** Japan is a region with historically high dietary iodine intake, primarily from seaweed.137 JTA guidelines for Graves' disease discuss ATD therapy, RAI, and surgery.133 While the guidelines acknowledge that excessive iodine intake can cause transient hypothyroidism 139, specific recommendations for *restricting* dietary iodine in Graves' or Hashimoto's patients in Japan are not a prominent feature of the English-language guideline summaries available, likely due to the baseline high-iodine environment. The focus is often on managing the thyroid condition with standard therapies within that context. JTA guidelines for thyroid nodules are also under preparation or have been revised, focusing on diagnosis and management pathways.137
* **Korean Thyroid Association (KTA):** Korea is also an iodine-replete area.71 KTA guidelines for thyroid nodules (2023) focus on US-based risk stratification (K-TIRADS) and FNA criteria but do not provide specific dietary iodine advice for nodule management itself.146 For RAI therapy preparation, the KTA recommends a LID of less than 100 µg/day, which is less strict than the ATA's <50 µg/day, acknowledging the challenges in an iodine-rich dietary environment.144 KTA guidelines for subclinical hypothyroidism (2023) emphasize Korean-specific TSH reference ranges but do not detail dietary iodine management for Hashimoto's.150 For Graves' disease, KTA reports indicate ATDs are the preferred initial treatment, similar to trends elsewhere.151

A general theme across guidelines is the emphasis on avoiding both iodine deficiency and gross excess. However, for patients with established thyroid disease in iodine-sufficient regions, highly specific, quantified daily dietary iodine targets (outside of LID for RAI) are often lacking in major international guidelines, contributing to the aforementioned patient and clinician confusion.

### **D. Monitoring Iodine Status in Thyroid Patients**

Routine monitoring of iodine status (e.g., via urinary iodine concentration, UIC) in all patients with diagnosed thyroid disorders is **not** generally recommended by major clinical guidelines, especially in iodine-sufficient regions.25 UIC is primarily a tool for assessing iodine status at a *population* level, not for individual clinical decision-making in most thyroid disease contexts, due to significant day-to-day variability in iodine excretion.12

Indications for iodine testing in individual patients with thyroid disease are limited but might be considered in specific circumstances:

* **Suspected Iodine Deficiency as a Cause of Hypothyroidism or Goiter:** In regions where iodine deficiency is still prevalent, or if a patient has specific risk factors for deficiency (e.g., highly restrictive diets, veganism with no iodized salt or supplement use) and presents with hypothyroidism or goiter, assessing iodine status might be considered to guide potential supplementation.9
* **Evaluation Before and After Exposure to High Iodine Loads:** For patients at high risk of iodine-induced thyroid dysfunction (e.g., those with pre-existing thyroid autoimmunity or nodular goiter) who are exposed to ICM or amiodarone, baseline thyroid function tests are crucial. Follow-up thyroid function tests are recommended to detect any induced dysfunction.10 Direct iodine status measurement is less common here than monitoring thyroid function itself.
* **Research Settings:** Quantified iodine intake or UIC is often measured in research studies investigating the links between iodine and thyroid disease progression or treatment outcomes.49

For most thyroid patients in iodine-sufficient areas, clinical management relies on assessing thyroid function tests (TSH, free T4​, T3​ as appropriate) and thyroid antibody levels, rather than routine iodine status monitoring. The focus is on achieving euthyroidism with appropriate medical therapy and advising on a balanced diet that avoids extremes of iodine intake.

## **IX. Conclusion: The Imperative of Individualized Iodine Management**

The role of iodine in thyroid health is undeniably profound, acting as an essential substrate for hormone synthesis while also possessing the potential to disrupt thyroid function when intake is imbalanced. For individuals with thyroid disease, the question of whether to control iodine intake does not have a universal answer; rather, it necessitates a nuanced, individualized approach guided by the specific thyroid condition, the underlying cause, the patient's overall health status, regional iodine availability, and current medical treatments.

**Key Synthesized Findings:**

1. **Iodine is Essential, but Balance is Paramount:** Both iodine deficiency and iodine excess can lead to or exacerbate thyroid dysfunction. Deficiency is a primary cause of hypothyroidism and goiter globally, while excess can trigger or worsen hypothyroidism (especially in Hashimoto's), hyperthyroidism (particularly in Graves' disease or those with autonomous nodules), and potentially fuel autoimmune processes.
2. **Hypothyroidism Management:**
   * In iodine-sufficient regions where Hashimoto's thyroiditis is the predominant cause of hypothyroidism, routine iodine supplementation is generally **not recommended** and can be harmful. Excess iodine may worsen autoimmunity in Hashimoto's.
   * The focus is on thyroid hormone replacement (levothyroxine). Some practitioners advocate for lower iodine intake in Hashimoto's, but this is an area of ongoing debate and lacks universal endorsement from major thyroid associations for all patients. Avoiding overt iodine excess from supplements and extremely high-iodine foods is a prudent general approach.
3. **Hyperthyroidism Management:**
   * Patients with hyperthyroidism, especially Graves' disease and toxic nodular goiter, should generally **avoid excess iodine** from diet and supplements, as it can worsen the condition or interfere with antithyroid drug (ATD) efficacy.
   * Emerging evidence for Graves' disease suggests that maintaining *adequate* (not deficient or excessive) iodine intake during ATD treatment may be associated with better outcomes and lower recurrence rates than strict iodine restriction, though more research is needed to define precise optimal levels.
4. **Thyroid Nodules and Goiter:**
   * Iodine deficiency is a major risk factor for goiter and thyroid nodule formation.
   * The impact of iodine excess on nodule development is less clear, with inconsistent findings.
   * For individuals with existing nodules in iodine-sufficient areas, the primary dietary advice is to maintain iodine sufficiency and avoid extremes, rather than specific restrictions, unless preparing for RAI therapy.
5. **Sources of Iodine Require Vigilance:**
   * Dietary iodine content is highly variable, particularly in foods like seaweed and dairy. Iodized salt is a key public health tool but requires awareness for those needing to restrict intake.
   * High-dose iodine supplements (especially kelp) pose a significant risk of overconsumption and are generally contraindicated for most thyroid patients unless a specific deficiency is diagnosed and supplementation is medically supervised.
   * Medications (e.g., amiodarone) and iodinated contrast media represent substantial iodine loads that can induce thyroid dysfunction in susceptible individuals, necessitating awareness and potential monitoring.
6. **Goitrogenic Foods:**
   * In iodine-sufficient individuals, moderate consumption of cooked goitrogenic foods is generally safe and nutritious. The concern about these foods is often overstated for most thyroid patients. Caution with excessive raw intake may be warranted for some with active hypothyroidism.
7. **Significant Knowledge Gaps and Patient Confusion Persist:**
   * Definitive, universally accepted guidelines for precise daily dietary iodine targets for specific autoimmune thyroid conditions (beyond general RDA/UL and avoiding gross excess/deficiency) are lacking.
   * This contributes to considerable patient confusion, fueled by conflicting advice from various sources.
   * More research is needed on optimal iodine windows, long-term effects of moderate iodine variations on treated thyroid disease, interactions with medications, and individual variability in response to iodine.

**Recommendations for Thyroid Patients:**

1. **Consult Healthcare Professionals:** All decisions regarding iodine intake should be made in close consultation with an endocrinologist or a knowledgeable healthcare provider. Self-adjusting iodine intake or taking iodine supplements without medical advice can be harmful.
2. **Understand Your Specific Condition:** The appropriate approach to iodine depends heavily on the type of thyroid disease (e.g., Hashimoto's, Graves', non-autoimmune hypothyroidism, nodules), its cause, and current treatment.
3. **Avoid Iodine Supplements Unless Prescribed:** Do not take iodine or kelp supplements unless a healthcare provider has diagnosed iodine deficiency and specifically recommended them. Be wary of supplements marketed for general "thyroid support" that contain high doses of iodine.
4. **Be Aware of Dietary Iodine Sources:** Understand which foods are typically high in iodine (e.g., seaweed, iodized salt, dairy, eggs) and consume them in moderation, consistent with overall dietary balance and specific medical advice. If a low-iodine diet is prescribed (e.g., for RAI therapy), follow guidelines meticulously.
5. **Inquire About Iodine in Medications and Medical Procedures:** If you have a thyroid condition, discuss potential iodine content and thyroid effects of any new medications or upcoming medical imaging procedures (like CT scans with contrast) with your doctors.
6. **Focus on Overall Balanced Nutrition:** For most thyroid patients in iodine-sufficient regions, a balanced diet rich in fruits, vegetables, lean proteins, and whole grains, while avoiding extremes of iodine intake, is generally recommended.
7. **Seek Reliable Information:** Obtain information about thyroid health and diet from reputable sources, such as major thyroid associations (ATA, ETA), and discuss any questions or concerns with your healthcare provider.

In conclusion, while iodine is fundamental to thyroid function, its management in the context of thyroid disease is a nuanced affair. Moving beyond a simplistic "good" or "bad" view of iodine, patients and clinicians must work together to tailor iodine intake to individual needs, ensuring sufficiency while diligently avoiding harmful excess, to best support thyroid health and overall well-being. Continued research is vital to refine these personalized approaches and resolve existing controversies.

#### Works cited

1. Thyroid Disease: What It Is, Causes, Symptoms & Treatment - Cleveland Clinic, accessed May 31, 2025, <https://my.clevelandclinic.org/health/diseases/8541-thyroid-disease>
2. Hypothyroidism | American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/hypothyroidism/>
3. Graves' disease vs. Hashimoto's disease: What to know - Medical News Today, accessed May 31, 2025, <https://www.medicalnewstoday.com/articles/graves-disease-vs-hashimoto>
4. www.thyroid.org, accessed May 31, 2025, <https://www.thyroid.org/hypothyroidism/#:~:text=Too%20much%20or%20too%20little,can%20cause%20or%20worsen%20hypothyroidism.>
5. Hyperthyroidism - Life Extension, accessed May 31, 2025, <https://www.lifeextension.com/protocols/metabolic-health/hyperthyroidism>
6. Iodine - The Nutrition Source, accessed May 31, 2025, <https://nutritionsource.hsph.harvard.edu/iodine/>
7. Iodine - Health Professional Fact Sheet - NIH Office of Dietary Supplements, accessed May 31, 2025, <https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/>
8. Iodine and Thyroid Health | Anna Pinnock Nutrition, accessed May 31, 2025, <https://www.annapinnock.co.uk/articles/iodine-and-thyroid-health/>
9. Iodine | Linus Pauling Institute | Oregon State University, accessed May 31, 2025, <https://lpi.oregonstate.edu/mic/minerals/iodine>
10. ATA Statement on the Potential Risks of Excess Iodine Ingestion and ..., accessed May 31, 2025, <https://www.thyroid.org/ata-statement-on-the-potential-risks-of-excess-iodine-ingestion-and-exposure/>
11. From deficiency to excess: the impact of iodine excess on ... - Frontiers, accessed May 31, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1568059/full>
12. Iodine deficiency - World Health Organization (WHO), accessed May 31, 2025, <https://www.who.int/data/nutrition/nlis/info/iodine-deficiency>
13. 10 Foods for Thyroid Health—And 3 To Avoid, accessed May 31, 2025, <https://www.health.com/food/the-best-and-worst-foods-for-your-thyroid>
14. Goiter | American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/goiter/>
15. Iodine Intake is Associated with Thyroid Function in Mild to Moderately Iodine Deficient Pregnant Women - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6157349/>
16. Beyond thyroid dysfunction: the systemic impact of iodine excess - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11999837/>
17. Iodine Intake from Universal Salt Iodization Programs and Hashimoto's Thyroiditis: A Systematic Review - MDPI, accessed May 31, 2025, <https://www.mdpi.com/2079-9721/13/6/166>
18. Modern challenges of iodine nutrition: vegan and vegetarian diets - Frontiers, accessed May 31, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1537208/full>
19. Effects of Increased Iodine Intake on Thyroid Disorders - Endocrinology and Metabolism, accessed May 31, 2025, <https://www.e-enm.org/journal/view.php?doi=10.3803/enm.2014.29.3.240>
20. Iodine-induced thyroid dysfunction: a scientometric study and visualization analysis - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10548383/>
21. Hashimoto Thyroiditis - StatPearls - NCBI Bookshelf, accessed May 31, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK459262/>
22. Iodine-induced thyroid dysfunction: a scientometric study and visualization analysis, accessed May 31, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1239038/full>
23. Iodinated contrast media (ICM)-induced thyroid dysfunction: a review of potential mechanisms and clinical management | springermedizin.de, accessed May 31, 2025, <https://www.springermedizin.de/iodinated-contrast-media-icm-induced-thyroid-dysfunction-a-revie/50929072>
24. Iodine-induced thyroid dysfunction - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5661998/>
25. Risks of Iodine Excess | Endocrine Reviews - Oxford Academic, accessed May 31, 2025, <https://academic.oup.com/edrv/article/45/6/858/7693016>
26. Urinary Iodine Excretion and Serum Thyroid Function in Adults After Iodinated Contrast Administration - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4426305/>
27. A narrative review of long-term inorganic iodine monotherapy for Graves' disease with a historical relationship between iodine and thyroid - J-Stage, accessed May 31, 2025, <https://www.jstage.jst.go.jp/article/endocrj/72/1/72_EJ24-0186/_html/-char/en>
28. Iodinated contrast media (ICM)-induced thyroid dysfunction: a review of potential mechanisms and clinical management - PMC - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12040987/>
29. (PDF) Thyroid Autoimmunity During Universal Salt Iodisation ..., accessed May 31, 2025, <https://www.researchgate.net/publication/387003514_Thyroid_Autoimmunity_During_Universal_Salt_Iodisation-Possible_Short-Term_Modulation_with_Longer-Term_Stability>
30. Hypothyroidism: Should I take iodine supplements? - Mayo Clinic, accessed May 31, 2025, <https://www.mayoclinic.org/diseases-conditions/hypothyroidism/expert-answers/hypothyroidism-iodine/faq-20057929>
31. Hypothyroidism Information | Mount Sinai - New York, accessed May 31, 2025, <https://www.mountsinai.org/health-library/report/hypothyroidism>
32. Restoring Thyroid Hormone Balance | The Institute for Functional Medicine, accessed May 31, 2025, <https://www.ifm.org/articles/balancing-thyroid-hormones-naturally>
33. Hashimoto's Disease: What It Is, Symptoms & Treatment - Cleveland Clinic, accessed May 31, 2025, <https://my.clevelandclinic.org/health/diseases/17665-hashimotos-disease>
34. Hashimoto's disease - Symptoms & causes - Mayo Clinic, accessed May 31, 2025, <https://www.mayoclinic.org/diseases-conditions/hashimotos-disease/symptoms-causes/syc-20351855>
35. Excessive Iodine Promotes Pyroptosis of Thyroid Follicular Epithelial Cells in Hashimoto's Thyroiditis Through the ROS-NF-κB-NLRP3 Pathway - Frontiers, accessed May 31, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00778/full>
36. Hashimoto's Disease Diet: A Thyroid-Friendly Eating Plan - Rupa Health, accessed May 31, 2025, <https://www.rupahealth.com/post/hashimotos-disease-diet-a-thyroid-friendly-eating>
37. Thyroid disease and autoimmune diseases - Autoimmunity - NCBI Bookshelf, accessed May 31, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK459466/>
38. Iodine as a potential endocrine disruptor—a role of oxidative stress - PMC - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9584999/>
39. Excessive iodine induces thyroid follicular epithelial cells apoptosis by activating HIF-1α-mediated hypoxia pathway in Hashimoto thyroiditis - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10042978/>
40. The Thyroid Reset Diet: Reverse Hypothyroidism and Hashimoto's Symptoms with a Proven Iodine-Balancing Plan - Goodreads, accessed May 31, 2025, <https://www.goodreads.com/book/show/53285209-the-thyroid-reset-diet>
41. The Thyroid Reset Diet: Reverse Hypothyroidism and Hashimoto's Symptoms with a Proven Iodine-Balancing Plan - Amazon.com, accessed May 31, 2025, <https://www.amazon.com/Thyroid-Reset-Diet-Hypothyroidism-Iodine-Balancing-ebook/dp/B087B4CD4H>
42. The Iodine & Hashimoto's Question - Amy Myers MD, accessed May 31, 2025, <https://www.amymyersmd.com/blogs/articles/the-iodine-hashimoto-s-question>
43. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9478900/>
44. Levothyroxine - StatPearls - NCBI Bookshelf, accessed May 31, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK539808/>
45. Therapeutic efficacy and patient compliance of levothyroxine liquid and softgel formulations taken with meals: a systematic review - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11739177/>
46. Diets and supplements for thyroid disorders, accessed May 31, 2025, <https://www.btf-thyroid.org/diets-and-supplements-for-thyroid-disorders>
47. Evaluation of Health-Related Quality of Life in Patients with Euthyroid Hashimoto's Thyroiditis under Long-Term Levothyroxine Therapy: A Prospective Case-Control Study - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11173285/>
48. No Association Between Diet Quality, Nutritional Status, and Quality of Life in Women with Hashimoto's Thyroiditis—A Cross-Sectional Study - MDPI, accessed May 31, 2025, <https://www.mdpi.com/2072-6643/17/6/1015>
49. Effect of small doses of iodine on thyroid function in patients with Hashimoto's thyroiditis residing in an area of mild iodine deficiency - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/9703374/>
50. Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves' disease: a systemic review, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10600371/>
51. Hyperthyroidism | Graves' Disease | Overactive Thyroid | MedlinePlus, accessed May 31, 2025, <https://medlineplus.gov/hyperthyroidism.html>
52. Iodine Toxicity - StatPearls - NCBI Bookshelf, accessed May 31, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK560770/>
53. Graves' Disease - American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/graves-disease/>
54. Management Aspects of Medical Therapy in Graves Disease - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12005956/>
55. Dietary Treatment of Graves' Disease: Reviewing The Evidence, accessed May 31, 2025, <https://www.dietvsdisease.org/dietary-treatment-graves-disease/>
56. Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves' disease: a systemic review - Frontiers, accessed May 31, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1234918/full>
57. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/29288501/>
58. Toxic Nodule and Toxic Multinodular Goiter - American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/toxic-nodule-multinodular-goiter/>
59. Thyroid nodules - Symptoms & causes - Mayo Clinic, accessed May 31, 2025, <https://www.mayoclinic.org/diseases-conditions/thyroid-nodules/symptoms-causes/syc-20355262>
60. Thyroid Nodules | Endocrine Society, accessed May 31, 2025, <https://www.endocrine.org/patient-engagement/endocrine-library/thyroid-nodules>
61. Subclinical Hyperthyroidism: When to Consider Treatment - AAFP, accessed May 31, 2025, <https://www.aafp.org/pubs/afp/issues/2017/0601/p710.html>
62. Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter - Oxford Academic, accessed May 31, 2025, <https://academic.oup.com/edrv/article/26/4/504/2355182?login=true>
63. Goitre - Causes, investigation and management - RACGP, accessed May 31, 2025, <https://www.racgp.org.au/afp/2012/august/goitre>
64. Multinodular Goiter - Endotext - NCBI Bookshelf, accessed May 31, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK285569/>
65. Goiter - StatPearls - NCBI Bookshelf, accessed May 31, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK562161/>
66. Graves' Disease: What It Is, Symptoms & Treatment - Cleveland Clinic, accessed May 31, 2025, <https://my.clevelandclinic.org/health/diseases/15244-graves-disease>
67. Long term outcomes of patients with Graves' Disease - American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/patient-thyroid-information/ct-for-patients/february-2024/vol-17-issue-2-p-7-8/>
68. Antithyroid Drug Treatment in Graves' Disease - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8258321/>
69. Antithyroid Drug Treatment in Graves' Disease - Endocrinology and Metabolism, accessed May 31, 2025, <https://www.e-enm.org/journal/view.php?number=2177>
70. Antithyroid Drug Treatment in Graves' Disease - Endocrinology and Metabolism, accessed May 31, 2025, <https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2021.1070>
71. Excessive Iodine Intake Does Not Increase the Recurrence Rate of Graves' Disease after Withdrawal of the Antithyroid Drug in an Iodine-Replete Area - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4404893/>
72. A systematic review and meta-analysis on the relationship between iodine and thyroid nodule - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/40434566/>
73. Management of Simple Nodular Goiter: Current Status and Future Perspectives | Endocrine Reviews | Oxford Academic, accessed May 31, 2025, <https://academic.oup.com/edrv/article/24/1/102/2424321>
74. Thyroid nodules: Symptoms, treatment, causes, and pictures - Medical News Today, accessed May 31, 2025, <https://www.medicalnewstoday.com/articles/185672>
75. Euthyroid Goiter With and Without Nodules—Diagnosis and Treatment - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3441105/>
76. Iodine Deficiency and Iodine Prophylaxis: An Overview and Update - PMC - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9967346/>
77. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4490680/>
78. Analysis of factors influencing prevalence and malignancy of thyroid nodules in various iodine uptake areas - Frontiers, accessed May 31, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1451911/full>
79. Approach to the Pediatric Patient With Thyroid Nodules | The ..., accessed May 31, 2025, <https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgaf090/8010905>
80. Effects of Overweight on Risk of Thyroid Nodules in Children and Adolescents: The Fukushima Health Management Survey - Oxford Academic, accessed May 31, 2025, <https://academic.oup.com/jcem/article/110/2/e478/7627891>
81. Changes of Nodular Size and Its Risk Factors in Iodine-Sufficient Area: a Retrospective Cohort Analysis of 7753 Thyroid Nodules - International Journal of Thyroidology, accessed May 31, 2025, <https://www.ijthyroid.org/journal/view.html?doi=10.11106/ijt.2020.13.2.118>
82. Thyroid Ultrasonography: Much Ado About Nothing? A Provocative Analysis - MDPI, accessed May 31, 2025, <https://www.mdpi.com/2072-6694/17/11/1764>
83. Beyond thyroid dysfunction: the systemic impact of iodine excess - Frontiers, accessed May 31, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1568807/full>
84. Iodine - Consumer - NIH Office of Dietary Supplements, accessed May 31, 2025, <https://ods.od.nih.gov/factsheets/Iodine-Consumer/>
85. Goiter - Diagnosis & treatment - Mayo Clinic, accessed May 31, 2025, <https://www.mayoclinic.org/diseases-conditions/goiter/diagnosis-treatment/drc-20351834>
86. Best and Worst Foods For Your Thyroid - The Marion Gluck Clinic, accessed May 31, 2025, <https://www.mariongluckclinic.com/blog/best-worst-foods-for-your-thyroid.html>
87. Hypothyroidism Diet: Foods to Eat and Avoid for Better Thyroid Health, accessed May 31, 2025, <https://www.verywellhealth.com/hypothyroidism-diet-8748574>
88. USDA, FDA, and ODS-NIH Database for the Iodine Content of Common Foods, accessed May 31, 2025, <https://www.ars.usda.gov/ARSUSERFILES/80400535/DATA/IODINE/IODINE%20DATABASE_RELEASE_2_DOCUMENTATION.PDF>
89. Best Iodine Supplements For Thyroid Support | Dr. Will Cole, accessed May 31, 2025, <https://drwillcole.com/vitamins-herbs/best-iodine-supplements>
90. Foods To Avoid if You Have Thyroid Issues - Cleveland Clinic Health Essentials, accessed May 31, 2025, <https://health.clevelandclinic.org/thyroid-issues-what-you-need-to-know-about-diet-and-supplements>
91. USDA, FDA and ODS-NIH Database for the Iodine Content of Common Foods, accessed May 31, 2025, <https://www.ars.usda.gov/ARSUSERFILES/80400535/DATA/IODINE/IODINE%20DATABASE_DOCUMENTATION.PDF>
92. Low Iodine Diet - American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/low-iodine-diet/>
93. Low-Iodine Cookbook by ThyCa: Thyroid Cancer Survivors Association, accessed May 31, 2025, <https://thyca.org/Cookbook.pdf>
94. American Thyroid Association (ATA) Issues Statement On The Potential Risks Of Excess Iodine Ingestion And Exposure, accessed May 31, 2025, <https://www.thyroid.org/american-thyroid-association-ata-issues-statement-on-the-potential-risks-of-excess-iodine-ingestion-and-exposure/>
95. Consensus Statement #2 American Thyroid Association Statement on Early Maternal Thyroidal Insufficiency: Recognition, Clinical Management and Research Directions, accessed May 31, 2025, <http://www.thyroid.org/wp-content/uploads/statements/ATAPregGuide.pdf>
96. 2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8314764/>
97. 2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction in, accessed May 31, 2025, <https://etj.bioscientifica.com/view/journals/etj/10/4/ETJ517175.xml>
98. Bismuth Chelate-Mediated Computed Tomography Perfusion Imaging of Acute Ischemic Stroke In Vivo | ACS Applied Materials & Interfaces - ACS Publications, accessed May 31, 2025, <https://pubs.acs.org/doi/10.1021/acsami.5c02378>
99. Iodine-Induced Hyperthyroidism and Long-term Risks of Incident Atrial Fibrillation and Flutter | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed May 31, 2025, <https://academic.oup.com/jcem/article/108/10/e956/7153260>
100. Goitrogens and Thyroid Disease - Verywell Health, accessed May 31, 2025, <https://www.verywellhealth.com/thyroid-disease-goitrogens-diet-3233164>
101. Goiter | Endocrinology and Diabetes - UC Davis Health, accessed May 31, 2025, <https://health.ucdavis.edu/conditions/endocrinology-diabetes/thyroid-disorders/goiter>
102. Goitrogenic Foods and Their Impact on Thyroid Health - Integrative Healthwerks, accessed May 31, 2025, <https://integrativehealthwerks.com/goitrogenic-foods-and-their-impact-on-thyroid-health/>
103. Influence of goitrogenic foods intake on thyroid - ProQuest, accessed May 31, 2025, <https://www.proquest.com/scholarly-journals/influence-goitrogenic-foods-intake-on-thyroid/docview/1769624849/se-2>
104. Hashimoto's and Diet - Girls Gone Strong, accessed May 31, 2025, <https://www.girlsgonestrong.com/blog/articles/hashimotos-and-diet-what-to-eat-and-what-to-avoid/>
105. Thyroid Nodules | American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/thyroid-nodules/>
106. Assessing ChatGPT's Capability in Addressing Thyroid Cancer Patient Queries: A Comprehensive Mixed-Methods Evaluation | Journal of the Endocrine Society | Oxford Academic, accessed May 31, 2025, <https://academic.oup.com/jes/article/9/2/bvaf003/7952046>
107. Experiences with a low-iodine diet: A qualitative study of patients with thyroid cancer receiving radioactive iodine therapy - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/27456374/>
108. Thyroid cancer: patients' experiences of receiving iodine-131 therapy - ResearchGate, accessed May 31, 2025, <https://www.researchgate.net/publication/12309622_Thyroid_cancer_patients'_experiences_of_receiving_iodine-131_therapy>
109. Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8764339/>
110. Iodoprophylaxis and thyroid autoimmunity: an update - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8106604/>
111. Iodine activates NLRP3 inflammasomes in PBMCs of patients with autoimmune thyroiditis and regulates Th1 and Th17 cell differenti - Endocrine Connections, accessed May 31, 2025, <https://ec.bioscientifica.com/view/journals/ec/14/2/EC-24-0456.pdf>
112. Long-term follow-up of treatment outcomes in Graves' disease and toxic nodular disease, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/39152296/>
113. Excessive Iodine Intake During Lactation Is Not Related to the Incidence of Thyroid Disease: A 3-Year Follow-Up Study - MDPI, accessed May 31, 2025, <https://www.mdpi.com/2072-6643/17/3/476>
114. Iodine‐Induced Hypothyroidism and Long‐Term Risks of Incident Heart Failure, accessed May 31, 2025, <https://www.ahajournals.org/doi/10.1161/JAHA.123.030511>
115. Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories, accessed May 31, 2025, <https://jnm.snmjournals.org/content/66/4/525>
116. Urinary iodine levels and thyroid disorder prevalence in the adult population of China, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12022125/>
117. Association between long-term exposure to PM2.5 and thyroid nodules in school-aged children and adolescents: a cross-sectional study in Eastern China - PMC - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11974047/>
118. Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights - PMC - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11964482/>
119. The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12027515/>
120. Recent advances in gut microbiota and thyroid disease: pathogenesis and therapeutics in autoimmune, neoplastic, and nodular conditions - Frontiers, accessed May 31, 2025, <https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1465928/full>
121. A Comprehensive Review of Selenium as a Key Regulator in Thyroid Health, accessed May 31, 2025, <https://www.researchgate.net/publication/391705943_A_Comprehensive_Review_of_Selenium_as_a_Key_Regulator_in_Thyroid_Health>
122. Papillary / Follicular - Low-Iodine Diet - ThyCa, accessed May 31, 2025, <https://thyca.org/pap-fol/lowiodinediet/>
123. Papillary / Follicular - More Resources - ThyCa, accessed May 31, 2025, <https://thyca.org/pap-fol/treating-recurrent-or-persistent-disease-support/>
124. Patients Portal | Thyroid Information - American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/patient-thyroid-information/>
125. Graves' Disease and Thyroid Foundation, accessed May 31, 2025, <https://www.gdatf.org/>
126. Resources | Graves' Disease and Thyroid Foundation, accessed May 31, 2025, <https://www.gdatf.org/resources/>
127. accessed January 1, 1970, <https://www.gdatf.org/news-events/patient-bulletins/>
128. accessed January 1, 1970, <https://www.thyroid.org/thyroid-health-blog/>
129. ATA Guidelines & Statements - American Thyroid Association, accessed May 31, 2025, <https://www.thyroid.org/professionals/ata-professional-guidelines/>
130. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum - ThyCa, accessed May 31, 2025, <https://thyca.org/wp-content/uploads/et-al-2011-guidelines-of-the-american-thyroid-association-for-the-diagnosis-and-management-of-thyroid-disease-during.pdf>
131. Guidelines - eurothyroid.com - European Thyroid Association, accessed May 31, 2025, <https://www.eurothyroid.com/guidelines/eta_guidelines.html>
132. 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease - PMC - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9142815/>
133. Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016, accessed May 31, 2025, <https://www.researchgate.net/publication/316346912_Guidelines_for_the_treatment_of_childhood-onset_Graves'_disease_in_Japan_2016>
134. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management - PMC - PubMed Central, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10448590/>
135. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/37358008/>
136. The ETA–ESE statement on the European Chemicals Agency opinion on iodine as an endocrine disruptor, accessed May 31, 2025, <https://www.eurothyroid.com/files/download/ETA-ESE-statement-iodine-endocrine-disruptor.pdf>
137. Hot News & Views｜Japan Thyroid Association - 日本甲状腺学会, accessed May 31, 2025, <https://www.japanthyroid.jp/en/hot_news.html>
138. Association between dietary iodine intake and prevalence of subclinical hypothyroidism in the coastal regions of Japan - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/8106628/>
139. Guidelines｜Japan Thyroid Association - 日本甲状腺学会, accessed May 31, 2025, <https://www.japanthyroid.jp/en/guidelines.html>
140. Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016 - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5402306/>
141. Survey of the actual administration of thiamazole for hyperthyroidism in Japan by the Japan Thyroid Association - J-Stage, accessed May 31, 2025, <https://www.jstage.jst.go.jp/article/endocrj/69/1/69_EJ21-0238/_html/-char/en>
142. The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/40058844/>
143. Introducing the reporting system for thyroid fine-needle aspiration cytology according to the new guidelines of the Japan Thyroid Association - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/24727657/>
144. The Impact of Low Adherence to the Low-iodine Diet on the Efficacy of the Radioactive Iodine Ablation Therapy - KoreaMed Synapse, accessed May 31, 2025, <https://synapse.koreamed.org/articles/1059809>
145. Analysis of Iodine Content in Salts and Korean Sauces for Low-Iodine Diet Education in Korean Patients with Thyroid Cancer Preparing for Radioiodine Therapy, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5995774/>
146. A Narrative Review of the 2023 Korean Thyroid Association Management Guideline for Patients with Thyroid Nodules - Endocrinology and Metabolism, accessed May 31, 2025, <https://www.e-enm.org/journal/view.php?number=2464>
147. A Narrative Review of the 2023 Korean Thyroid Association Management Guideline for Patients with Thyroid Nodules - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/38356209/>
148. The Revised 2016 Korean Thyroid Association Guidelines for Thyroid Nodules and Cancers: Differences from the 2015 American Thyroid Association Guidelines - PMC, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5053047/>
149. A Narrative Review of the 2023 Korean Thyroid Association Management Guideline for Patients with Thyroid Nodules, accessed May 31, 2025, <https://www.e-enm.org/journal/view.php?viewtype=pubreader&number=2464>
150. Management of Subclinical Hypothyroidism: A Focus on Proven Health Effects in the 2023 Korean Thyroid Association Guidelines, accessed May 31, 2025, [https://synapse.koreamed.org/func/download.php?path=L2hvbWUvdmlydHVhbC9rYW1qZS9zeW5hcHNlL3VwbG9hZC9TeW5hcHNlWE1MLzIwMDhlbm0vcGRmL2VubS0yMDIzLTE3NzgucGRm&filename=ZW5tLTIwMjMtMTc3OC5wZGY=](https://synapse.koreamed.org/func/download.php?path=L2hvbWUvdmlydHVhbC9rYW1qZS9zeW5hcHNlL3VwbG9hZC9TeW5hcHNlWE1MLzIwMDhlbm0vcGRmL2VubS0yMDIzLTE3NzgucGRm&filename=ZW5tLTIwMjMtMTc3OC5wZGY%3D)
151. Consensus Report of the Korean Thyroid Association - KoreaMed Synapse, accessed May 31, 2025, <https://synapse.koreamed.org/articles/1086031>
152. accessed January 1, 1970, <https://www.thyroid.org/iodine-deficiency/>
153. Urinary Iodine Concentration and Thyroid Hormone Metabolism in Pregnant Women and Neurodevelopment in Their Children: A Longitudinal Canadian Birth Cohort - MDPI, accessed May 31, 2025, <https://www.mdpi.com/2072-6643/17/5/830>
154. Longitudinal trends in thyroid function in relation to iodine intake - CiteSeerX, accessed May 31, 2025, <https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=0517fc9d16c1868aef2a4c82c967f557d0a7f9b7>
155. Urinary Iodine Concentration and Thyroid Hormone Metabolism in Pregnant Women and Neurodevelopment in Their Children: A Longitudinal Canadian Birth Cohort - PubMed, accessed May 31, 2025, <https://pubmed.ncbi.nlm.nih.gov/40077700/>
156. The Prevalence of Thyroid Dysfunction in Elderly Cardiology Patients with Mild Excessive Iodine Intake in the Urban Area of SÃ - Elsevier, accessed May 31, 2025, <https://www.elsevier.es/index.php?p=revista&pRevista=pdf-simple&pii=S1807593222026928&r=22>
157. The SELFI Study: Iodine Excess and Thyroid Dysfunction in Women Undergoing Oil-Soluble Contrast Hysterosalpingography, accessed May 31, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9693785/>